SI3307296T1 - TIMP2 za uporabo pri zdravljenju s starostjo povezanih stanj - Google Patents

TIMP2 za uporabo pri zdravljenju s starostjo povezanih stanj

Info

Publication number
SI3307296T1
SI3307296T1 SI201631420T SI201631420T SI3307296T1 SI 3307296 T1 SI3307296 T1 SI 3307296T1 SI 201631420 T SI201631420 T SI 201631420T SI 201631420 T SI201631420 T SI 201631420T SI 3307296 T1 SI3307296 T1 SI 3307296T1
Authority
SI
Slovenia
Prior art keywords
timp2
associated conditions
treating aging
aging
treating
Prior art date
Application number
SI201631420T
Other languages
English (en)
Inventor
Anton Wyss-Coray
Joseph M. Castellano
Original Assignee
The Board of Trustees of the Leland Stanford Junior University Office of the General Counsel
U.S. Government As Represented By The Department Of Veterans Affairs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Board of Trustees of the Leland Stanford Junior University Office of the General Counsel, U.S. Government As Represented By The Department Of Veterans Affairs filed Critical The Board of Trustees of the Leland Stanford Junior University Office of the General Counsel
Publication of SI3307296T1 publication Critical patent/SI3307296T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Treatments Of Macromolecular Shaped Articles (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SI201631420T 2015-06-15 2016-06-06 TIMP2 za uporabo pri zdravljenju s starostjo povezanih stanj SI3307296T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562175981P 2015-06-15 2015-06-15
PCT/US2016/036032 WO2016205004A2 (en) 2015-06-15 2016-06-06 Methods and compositions for treating aging-associated conditions
EP16812148.1A EP3307296B1 (en) 2015-06-15 2016-06-06 Timp2 for use in treating aging-associated conditions

Publications (1)

Publication Number Publication Date
SI3307296T1 true SI3307296T1 (sl) 2022-04-29

Family

ID=57545637

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201631420T SI3307296T1 (sl) 2015-06-15 2016-06-06 TIMP2 za uporabo pri zdravljenju s starostjo povezanih stanj

Country Status (16)

Country Link
US (3) US10617744B2 (sl)
EP (2) EP3307296B1 (sl)
JP (3) JP6921006B2 (sl)
KR (4) KR20220062668A (sl)
CN (2) CN107921085B (sl)
AU (1) AU2016279804B2 (sl)
CA (1) CA2989138C (sl)
DK (1) DK3307296T3 (sl)
EA (1) EA201890020A1 (sl)
ES (1) ES2902467T3 (sl)
HK (1) HK1247102A1 (sl)
IL (2) IL256243B (sl)
NZ (1) NZ738675A (sl)
PT (1) PT3307296T (sl)
SI (1) SI3307296T1 (sl)
WO (1) WO2016205004A2 (sl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160208011A1 (en) 2010-01-28 2016-07-21 The Board Of Trustees Of The Leland Stanford Junior University Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
US10487148B2 (en) 2010-01-28 2019-11-26 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating aging-associated impairments
WO2017120461A1 (en) 2016-01-08 2017-07-13 The Board Of Trustees Of The Leland Stanford Junior University Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
US9161968B2 (en) 2011-04-08 2015-10-20 The Board Of Trustees Of The Leland Stanford Junior University Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists
AU2014364182B2 (en) 2013-12-09 2019-03-07 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating aging-associated conditions
US10905779B2 (en) 2013-12-09 2021-02-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening human blood products comprising plasma using immunocompromised rodent models
EA201890020A1 (ru) 2015-06-15 2018-05-31 Зе Боард Оф Трастиз Оф Зе Леланд Стэнфорд Джуниор Юниверсити Способы и композиции для лечения ассоциированных со старением состояний
ES2975517T3 (es) 2016-04-28 2024-07-08 Alkahest Inc Fracciones de plasma como terapia para el cáncer de timo
EA039316B1 (ru) 2016-10-24 2022-01-12 Алкахест, Инк. Фракции плазмы крови в качестве лечения когнитивных расстройств, связанных со старением
US11040068B2 (en) 2017-04-26 2021-06-22 Alkahest, Inc. Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
DK3615057T3 (da) 2017-04-26 2024-01-02 Alkahest Inc Doseringsskema til behandling af kognitive svækkelser med blodplasmaprodukter
JP7504090B2 (ja) 2018-10-26 2024-06-21 アルカヘスト，インコーポレイテッド 疼痛、創傷治癒及び術後回復の改善のための血漿及び血漿画分の使用
JP7396681B2 (ja) * 2018-12-17 2023-12-12 株式会社夏目綜合研究所 脳疾患の診断装置
US20230399380A1 (en) * 2022-05-17 2023-12-14 Alkahest, Inc. Methods and Compositions for Treating Aging-Associated Impairments with TIMP-2 Recombinant Proteins

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4708713A (en) 1984-11-16 1987-11-24 Anisa Medical, Inc. Method and system for removing immunosuppressive components from the blood of mammals
US4770774A (en) 1985-09-19 1988-09-13 Toray Industries, Inc. Column for removing β2 -microglobulin
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
DE3887114D1 (de) 1987-12-11 1994-02-24 Akzo Nv Biocompatible Dialysemembran aus Cellulose mit erhöhter Beta-2-Microglobulinadsorption.
JP3156082B2 (ja) 1989-03-21 2001-04-16 アメリカ合衆国 マトリックスメタロプロテイナーゼ阻害剤ペプチド
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5240614A (en) 1992-01-10 1993-08-31 Baxter International Inc. Process for removing unwanted materials from fluids and for producing biological products
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US6544761B2 (en) * 1994-12-13 2003-04-08 Human Genome Sciences, Inc. Human tissue inhibitor of metalloproteinase-4
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
GB9607287D0 (en) 1996-04-09 1996-06-12 British Biotech Pharm Diagnosis method
JP4215277B2 (ja) 1996-08-09 2009-01-28 アルコン ラボラトリーズ，インコーポレイテッド シクロデキストリンを含有する薬学的組成物用防腐剤系
US5916202A (en) 1996-08-30 1999-06-29 Haswell; John N. Umbilical cord blood collection
US6022948A (en) * 1996-09-17 2000-02-08 Washington University Method of cell surface activation and inhibition
US5904663A (en) 1997-07-30 1999-05-18 Braverman; Andrew Method of removing beta-2 microglobulin from blood
US20020159995A1 (en) 1997-07-30 2002-10-31 Renal Tech International Devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood, generated as a result of extracorporeal blood processing
US6416487B1 (en) 1997-07-30 2002-07-09 Renal Tech International Llc Method of removing beta-2 microglobulin from blood
US5985263A (en) 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
AUPP790898A0 (en) 1998-12-23 1999-01-28 Life Therapeutics Limited Renal dialysis
AUPR748501A0 (en) 2001-09-04 2001-09-27 Life Therapeutics Limited Renal dialysis
AU1853600A (en) 1999-01-06 2000-07-24 Choong-Chin Liew Method for the detection of gene transcripts in blood and uses thereof
CA2358949A1 (en) 1999-01-22 2000-07-27 Robert M. Strom Surface modified divinylbenzene resin having a hemocompatible coating
JP4342027B2 (ja) * 1999-04-01 2009-10-14 オリエンタル酵母工業株式会社 Ｔｉｍｐ修飾体
UA35656C2 (uk) 1999-12-27 2001-04-16 Олександр Миколайович Макаренко Спосіб лікування безперервно прогредієнтних ослабоумлюючих психічних захворювань
US7582292B2 (en) 2000-02-26 2009-09-01 Artecel, Inc. Adipose tissue derived stromal cells for the treatment of neurological disorders
US6946546B2 (en) 2000-03-06 2005-09-20 Cambridge Antibody Technology Limited Human antibodies against eotaxin
GB0015761D0 (en) * 2000-06-27 2000-08-16 Univ Bristol Polypeptide
US6632174B1 (en) 2000-07-06 2003-10-14 Cognifit Ltd (Naiot) Method and apparatus for testing and training cognitive ability
US20020151064A1 (en) 2001-02-07 2002-10-17 Children's Hospital Medical Center Regulation of CCR3 expression
US6475161B2 (en) 2001-03-29 2002-11-05 The Mclean Hospital Corporation Methods for diagnosing Alzheimer's disease and other forms of dementia
WO2003006006A1 (en) 2001-07-09 2003-01-23 The Regents Of The University Of California Use of matrix metalloproteinase inhibitors to mitigate nerve damage
WO2003025122A2 (en) 2001-08-13 2003-03-27 University Of Kentucky Research Foundation Gene expression profile biomarkers and therapeutic targets for brain aging and age-related cognitive impairment
US6906036B2 (en) 2001-08-16 2005-06-14 Kimberly-Clark Worldwide, Inc. Anti-aging and wound healing compounds
US7608406B2 (en) 2001-08-20 2009-10-27 Biosite, Inc. Diagnostic markers of stroke and cerebral injury and methods of use thereof
US8105580B2 (en) 2001-12-07 2012-01-31 Cytori Therapeutics, Inc. Methods of using adipose derived stem cells to promote wound healing
KR100441384B1 (ko) 2002-01-08 2004-07-21 주식회사 안지오랩 인간 혈청 알부민-팀프-2 융합 단백질 발현시스템 및재조합 인간 혈청 알부민-팀프-2 융합 단백질
US20050142101A1 (en) 2002-05-10 2005-06-30 Ulf Forssmann Method of inhibiting the emigration of cells from the intravascular compartment into tissues
EP1394549A1 (en) 2002-08-23 2004-03-03 Bayer HealthCare AG Biomarkers for diagnosing Alzheimer's disease
EP2221620B1 (en) 2002-08-23 2013-10-02 Bayer Pharma Aktiengesellschaft Polypeptide biomarkers for diagnosing Alzheimer's disease
US20040127445A1 (en) 2002-08-28 2004-07-01 Chondrogene Limited Beta-2 microglobulin (B2M) and B2M related gene products for the regulation of osteoarthritis pathogenesis and chondrocyte proliferation
US20050244448A1 (en) * 2002-10-14 2005-11-03 The Board Of Trustees Of The Leland Stanford Jr. University Diagnosis and treatment of disorders of collagen and elastin metabolism
US20040120937A1 (en) 2002-12-19 2004-06-24 Therapy Patent Corporation Blood therapy process
US7060795B2 (en) * 2002-12-19 2006-06-13 Kimberly-Clark Worldwide, Inc. Wound care compositions
WO2004060425A2 (en) 2002-12-27 2004-07-22 Angiotech International Ag Compositions and methods of using collagen and mmpi
US7785601B2 (en) 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
DK2284180T3 (en) 2003-03-03 2015-12-21 Dyax Corp Uses of peptides that specifically bind to the HGF receptor (cMET)
GB0305133D0 (en) 2003-03-06 2003-04-09 Sinvent As Product
DK1608374T5 (da) 2003-03-24 2010-01-25 Axikin Pharmaceuticals Inc 2-Phenoxy- og 2-phenylsulfanylbenzensulfonamidderivater med CCR3-antagonistisk aktivitet til behandling af astma og andre inflammatoriske eller immunologiske sygdomme
US20040254152A1 (en) 2003-04-17 2004-12-16 Monje Michelle L. Prevention of deficits in neurogenesis with anti-inflammatory agents
WO2004111608A2 (en) 2003-06-09 2004-12-23 Mcintyre John A Method of altering the binding specificity of plasma proteins by oxidation-reduction reactions
US20060094064A1 (en) 2003-11-19 2006-05-04 Sandip Ray Methods and compositions for diagnosis, stratification, and monitoring of alzheimer's disease and other neurological disorders in body fluids
ES2411455T3 (es) 2003-11-19 2013-07-05 Rules-Based Medicine, Inc. Procedimiento para el diagnóstico y la monitorización de la enfermedad de Alzheimer
US7794704B2 (en) 2004-01-23 2010-09-14 Advanced Cell Technology, Inc. Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration
WO2005106492A2 (en) 2004-04-30 2005-11-10 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with c-c chemokine receptor 3 (ccr3)
JP4908216B2 (ja) 2004-07-23 2012-04-04 株式会社カネカ 水不溶性微粒子を除去した吸着材を充填した直接血液灌流用吸着器、および水不溶性微粒子を除去した直接血液灌流用吸着材の取得方法
WO2006036928A2 (en) 2004-09-27 2006-04-06 Wayne State University Inhibitors of matrix metalloproteinases to treat neurological disorders
CA2590337C (en) 2004-12-15 2017-07-11 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
CA2638892A1 (en) 2005-03-18 2006-09-28 Oregon Health & Science University Recombinant mhc molecules useful for manipulation of antigen-specific t cells
WO2007041245A2 (en) 2005-09-29 2007-04-12 Biogen Idec Ma Inc. Biomarkers for multiple sclerosis and methods of use thereof
WO2007059135A2 (en) 2005-11-10 2007-05-24 Satoris, Inc. Methods of treating alzheimer's disease
US20080125354A1 (en) 2005-11-21 2008-05-29 Florida Atlantic University Selective inhibition of matrix metalloproteinases
US7908090B2 (en) 2005-11-30 2011-03-15 The Board Of Trustees Of The Leland Stanford Junior University Signatures for human aging
EP1988887A2 (en) 2006-01-13 2008-11-12 University of South Carolina Method and composition for the treatment of parkinson's disease
EP1986657A4 (en) 2006-02-16 2011-07-20 Discogen Llc METHOD OF TREATING A SUBJECT SUFFERING FROM DEGENERATIVE DISCOPATHY BY A MATRIX METALLOPROTEASE INHIBITOR
US10344095B2 (en) 2006-02-16 2019-07-09 University Of Kentucky Research Foundation CCR3 inhibition for ocular angiogenesis and macular degeneration
JP2009149524A (ja) 2006-03-16 2009-07-09 Kyushu Univ アルツハイマー病の予防・治療剤
WO2007123976A2 (en) 2006-04-18 2007-11-01 The Board Of Trustees Of The Leland Stanford Junior University Antibody profiling for determination of patient responsiveness
US20080057590A1 (en) 2006-06-07 2008-03-06 Mickey Urdea Markers associated with arteriovascular events and methods of use thereof
US7851172B2 (en) 2006-07-25 2010-12-14 University Of Kentucky Research Foundation Biomarkers of mild cognitive impairment and alzheimer's disease
US7592009B2 (en) * 2006-10-10 2009-09-22 Ecole Polytechnique Federale De Lausanne (Epfl) Polypeptide ligands for targeting cartilage and methods of use thereof
US8211310B2 (en) 2006-11-20 2012-07-03 Cytosorbents, Inc. Size-selective polymer system
WO2008106076A2 (en) * 2007-02-27 2008-09-04 Merck & Co., Inc. Methods for monitoring disease progression of alzheimer's disease using csf markers from longitudinal samples
WO2009008928A2 (en) 2007-04-13 2009-01-15 Stemnion, Inc. Methods for treating nervous system injury and disease
GB0710522D0 (en) 2007-06-01 2007-07-11 Royal Veterinary College The Drug delivery system comprising matrix metalloproteinase inhibitors
BRPI0815551A2 (pt) 2007-08-15 2015-02-18 Univ South Florida Tratamento através de hucbc de doença beta-amiloide
WO2009051660A2 (en) 2007-10-12 2009-04-23 The Board Of Trustees Of The Leland Stanford Junior University Compounds for activating tgf-beta signaling
US20100015235A1 (en) 2008-04-28 2010-01-21 Revalesio Corporation Compositions and methods for treating multiple sclerosis
US20100310609A1 (en) 2007-10-25 2010-12-09 Revalesio Corporation Compositions and methods for treatment of neurodegenerative diseases
US20090227018A1 (en) 2007-10-25 2009-09-10 Revalesio Corporation Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
EP2216060B2 (en) 2007-12-06 2021-03-17 Asahi Kasei Medical Co., Ltd. Porous hollow fiber membrane for blood treatment
AU2009241365B2 (en) * 2008-04-28 2015-01-22 Revalesio Corporation Compositions and methods for treating multiple sclerosis
CN102223896A (zh) 2008-08-07 2011-10-19 西塞医疗中心 抗-β-2-微球蛋白试剂及其用途
WO2010041617A1 (ja) 2008-10-09 2010-04-15 公立大学法人横浜市立大学 β－アミロイド前駆体蛋白質由来マトリックスメタロプロテアーゼ－２インヒビターペプチドと組織メタロプロテアーゼ阻害物質との融合タンパク質
US20100124756A1 (en) 2008-10-10 2010-05-20 Sandip Ray Collection of biomarkers for diagnosis and monitoring of alzheimer's disease in body fluids
US20110117100A1 (en) 2008-11-03 2011-05-19 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for diagnosis, stratification and treatment of amyloidogenic diseases
US8778616B2 (en) 2009-05-26 2014-07-15 University Of Kentucky Research Foundation Method of using CCR3 binding agents to detect choroidal neovascularization
US20160208011A1 (en) 2010-01-28 2016-07-21 The Board Of Trustees Of The Leland Stanford Junior University Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
WO2017120461A1 (en) 2016-01-08 2017-07-13 The Board Of Trustees Of The Leland Stanford Junior University Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
WO2011094535A2 (en) 2010-01-28 2011-08-04 The Board Of Trustees Of The Leland Stanford Junior University Biomarkers of aging for detection and treatment of disorders
US20110202284A1 (en) 2010-02-10 2011-08-18 Mcreynolds Cristopher Novel groups of biomarkers for diagnosing alzheimer's disease
RU2428997C1 (ru) 2010-03-01 2011-09-20 Федеральное государственное образовательное учреждение высшего профессионального образования Волгоградская государственная сельскохозяйственная академия Способ получения лечебных препаратов из пуповины плода
AR080698A1 (es) 2010-04-01 2012-05-02 Imclone Llc Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
BR112012027994B1 (pt) 2010-05-04 2021-10-13 Five Prime Therapeutics, Inc Anticorpo, composição farmacêutica e uso de um anticorpo
US9161968B2 (en) 2011-04-08 2015-10-20 The Board Of Trustees Of The Leland Stanford Junior University Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists
CN103827671B (zh) * 2011-05-03 2017-05-03 联邦科学与工业研究组织 用于检测神经疾病的方法
US9782457B2 (en) 2011-10-07 2017-10-10 Tissue Repair Company Flowable formulations for tissue repair and regeneration
RU2470677C1 (ru) 2011-10-19 2012-12-27 Надежда Михайловна Цулая Способ стимуляции репаративных и трофических процессов в коже
WO2013063086A1 (en) 2011-10-24 2013-05-02 Intellect Neurosciences, Inc. Compositions and methods for treatment of proteinopathies
US20150079045A1 (en) 2012-02-13 2015-03-19 Wuyi Kong Nprcps, pfdncs and uses thereof
MX2014011186A (es) 2012-03-20 2015-03-06 Einstein Coll Med Metodo para mejorar la eficiencia de las transfusiones de sangre.
US20130302322A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
RU2635560C2 (ru) 2012-10-29 2017-11-14 Чайна Петролеум Энд Кемикал Корпорейшн Способ адсорбционной десульфуризации углеводородов и реакторное устройство для его осуществления
EP2781523A1 (en) 2013-03-18 2014-09-24 Miltenyi Biotec GmbH Lipophilic oligonucleotide analogs
WO2015081166A1 (en) 2013-11-26 2015-06-04 University Of North Texas Health Science Center At Fort Worth Personalized medicine approach for treating cognitive loss
AU2014364182B2 (en) 2013-12-09 2019-03-07 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating aging-associated conditions
US10905779B2 (en) 2013-12-09 2021-02-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening human blood products comprising plasma using immunocompromised rodent models
AU2015247542A1 (en) 2014-04-16 2016-11-24 Blood Systems Research Institute Method and composition for conferring neuroprotection
EA035799B1 (ru) 2015-05-18 2020-08-12 Зе Боард Оф Трастиз Оф Зе Леланд Стэнфорд Джуниор Юниверсити Способ лечения взрослого млекопитающего от когнитивного нарушения, ассоциированного со старением
EA201890020A1 (ru) 2015-06-15 2018-05-31 Зе Боард Оф Трастиз Оф Зе Леланд Стэнфорд Джуниор Юниверсити Способы и композиции для лечения ассоциированных со старением состояний

Also Published As

Publication number Publication date
ES2902467T3 (es) 2022-03-28
EP3307296A4 (en) 2019-01-16
DK3307296T3 (da) 2021-12-13
KR102240347B1 (ko) 2021-04-15
US20200254075A1 (en) 2020-08-13
EP3307296A2 (en) 2018-04-18
EP4014984A1 (en) 2022-06-22
PT3307296T (pt) 2022-01-07
EP3307296B1 (en) 2021-10-20
CN107921085A (zh) 2018-04-17
WO2016205004A2 (en) 2016-12-22
IL256243A (en) 2018-02-28
CN107921085B (zh) 2021-10-22
CA2989138C (en) 2022-11-22
JP6921006B2 (ja) 2021-08-18
HK1247102A1 (zh) 2018-09-21
CN113855804A (zh) 2021-12-31
CA2989138A1 (en) 2016-12-22
KR20240025721A (ko) 2024-02-27
IL278004B2 (en) 2023-04-01
EA201890020A1 (ru) 2018-05-31
US20180353578A1 (en) 2018-12-13
AU2016279804B2 (en) 2019-03-07
JP2023082115A (ja) 2023-06-13
US11141469B2 (en) 2021-10-12
JP2018517726A (ja) 2018-07-05
KR20180025895A (ko) 2018-03-09
WO2016205004A3 (en) 2017-04-13
US10617744B2 (en) 2020-04-14
US20220016224A1 (en) 2022-01-20
NZ738675A (en) 2019-10-25
IL278004A (en) 2020-11-30
KR20220062668A (ko) 2022-05-17
JP2021176883A (ja) 2021-11-11
AU2016279804A1 (en) 2018-01-25
IL256243B (en) 2020-10-29
KR20210041137A (ko) 2021-04-14

Similar Documents

Publication Publication Date Title
SI3307296T1 (sl) TIMP2 za uporabo pri zdravljenju s starostjo povezanih stanj
ZA201704293B (en) Selective bace1 inhibitors
IL259992B (en) Compounds for use in methods for treating hyperalgesia
HK1244217A1 (zh) 用於治療蛋白質病的方法
GB201500989D0 (en) Process
GB201502893D0 (en) Process
GB201502894D0 (en) Process
GB201505311D0 (en) Process
GB201501952D0 (en) Process
IL249936A0 (en) Methods for treating hypotension
GB201501953D0 (en) Process
HUE064864T2 (hu) Az alprazolam alkalmazása epilepszia kezelésében
GB201503635D0 (en) Process
GB201500990D0 (en) Process
GB201504948D0 (en) Process
GB201502814D0 (en) Process
GB201501423D0 (en) Process
GB201503607D0 (en) Process
PL3311060T3 (pl) Nośnik rury
GB201523035D0 (en) In terferometry
GB201506536D0 (en) Process
GB201505981D0 (en) Process
GB201505712D0 (en) Process
GB201400311D0 (en) Treating Susceptibility
GB201513203D0 (en) New process